Eli Lilly and Company (NYSE:LLY) Price Target Raised to $1,600.00

Eli Lilly and Company (NYSE:LLY) had its target price lifted by equities research analysts at Cantor Fitzgerald from $1,440.00 to $1,600.00 in a research report issued on Monday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Cantor Fitzgerald‘s price objective indicates a potential upside of 13.02% from the stock’s current price.

Several other analysts also recently issued reports on LLY. Truist Financial reaffirmed a “buy” rating and issued a $1,612.00 price objective (up from $1,376.00) on shares of Eli Lilly and Company in a research report on Friday. Guggenheim lifted their price objective on shares of Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the company a “buy” rating in a research note on Friday, September 18th. The Goldman Sachs Group reissued a “buy” rating and set a $1,413.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, October 20th. Royal Bank Of Canada upped their target price on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company an “outperform” rating in a research note on Friday. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $1,650.00 price target on shares of Eli Lilly and Company in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,404.14.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $1,415.64 on Monday. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.39 and a quick ratio of 1.00. Eli Lilly and Company has a 1-year low of $834.19 and a 1-year high of $1,449.68. The company has a market capitalization of $1.33 trillion, a price-to-earnings ratio of 45.95, a PEG ratio of 1.80 and a beta of 0.40. The business has a 50-day moving average of $1,197.72 and a 200-day moving average of $1,092.57.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, October 29th. The company reported $7.48 EPS for the quarter, beating the consensus estimate of $5.71 by $1.77. The business had revenue of $24.40 billion for the quarter, compared to the consensus estimate of $22.58 billion. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The company’s revenue was up 38.6% on a year-over-year basis. During the same period last year, the business posted $7.02 EPS. On average, equities analysts anticipate that Eli Lilly and Company will post 35.18 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Patrik Jonsson sold 6,500 shares of the company’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the transaction, the executive vice president directly owned 11,875 shares in the company, valued at $14,131,250. This represents a 29.63% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 13,500 shares of company stock worth $15,958,170. 0.14% of the stock is owned by company insiders.

Institutional Investors Weigh In On Eli Lilly and Company

Several hedge funds have recently made changes to their positions in LLY. Marshall & Sterling Wealth Advisors Inc. lifted its position in shares of Eli Lilly and Company by 60.0% in the first quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock worth $37,000 after purchasing an additional 15 shares in the last quarter. Torren Management LLC grew its position in Eli Lilly and Company by 357.1% during the third quarter. Torren Management LLC now owns 32 shares of the company’s stock valued at $37,000 after purchasing an additional 25 shares in the last quarter. AlphaCentric Advisors LLC purchased a new position in Eli Lilly and Company during the first quarter valued at approximately $42,000. Foresight Capital Management Advisors Inc. acquired a new position in Eli Lilly and Company in the 3rd quarter valued at approximately $49,000. Finally, Caitlin John LLC purchased a new stake in Eli Lilly and Company in the 2nd quarter worth approximately $64,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Strong earnings and guidance underpin the rally. Eli Lilly reported third-quarter revenue growth of approximately 39%, led by Mounjaro and Zepbound, and raised its full-year outlook. The company reportedly delivered earnings and revenue above analyst expectations, helping drive the shares to record levels. Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?
• Positive Sentiment: Volume growth is offsetting lower prices. Coverage highlights that Eli Lilly grew revenue even after reducing GLP-1 prices by about 15%, suggesting demand remains strong and that lower prices could expand access to a larger patient market. Eli Lilly stock surges as cheaper drugs unlock a bigger market
• Positive Sentiment: Analyst confidence remains high. Several reports describe higher price targets, including targets near $1,600, while Keith McCullough reiterated his bullish LLY recommendation. Eli Lilly and Company Price Target Raised to $1,596.00
• Neutral Sentiment: Manufacturing expansion could support long-term growth. Goochland officials are considering a workforce-development pipeline linked to Eli Lilly’s planned $5 billion plant, which could help address future staffing needs. Goochland Weighs Direct Pipeline From High School Halls to Eli Lilly’s $5B Plant
• Negative Sentiment: Pricing and valuation are key risks. Medicare’s GLP-1 Bridge program and additional price cuts may pressure margins, while the stock’s sharp advance and premium valuation leave less room for execution disappointments. Optimistic long-term projections also acknowledge that future returns may be slower than the recent gains.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.